Venaxis is an in vitro diagnostic company pursuing clinical development and commercialization of APPY1, its blood-based appendicitis test. Designed to aid in identifying patients at low risk for acute appendicitis, thus enabling more conservative patient management, APPY1 is being initially developed for pediatric, adolescent and young adult patients with abdominal pain – this being the group with the highest risk for appendicitis and also the highest risk of long-term health effects from CT imaging. For more information, visit the company’s Web site at www.venaxis.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: